Neogene Therapeutics is a pre-clinical stage biotech pioneering fully personalized engineered T cell therapies that target neo-antigens — mutated proteins unique to each patient’s tumor. Its proprietary platform isolates neo-antigen–specific TCR genes from tumor biopsies using DNA sequencing, synthesis and genetic screening, then engineers those TCRs into patient T cells. The company emphasizes a syn‑bio based approach intended to improve standardization and scalability versus traditional TIL methods. Neogene was founded in 2018 by experienced cell therapy researchers and has demonstrated proof-of-concept for its platform via a 2019 seed financing. With the Series A, the company is expanding offices in Amsterdam and the U.S. and aims to initiate Phase I clinical studies in 2022.

Total raised

$110M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020